Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
PharmaNeuroBoost (PNB) announced today that it was invited to present the novel pharmacological concept of its clinical stage antipsychotic PNB02 at the upcoming NCDEU meeting in Phoenix, USA, on May 29th, 2012. This presentation will provide insight why augmentation of the golden standard antipsychotic risperidone with PNB’s proprietary compound, low dose pipamperone, can represent a beneficial treatment of schizophrenia patients who experience insufficient response to mono-treatment.
“The efficiency of schizophrenia treatment is often hampered by limited efficacy and the side-effects that occur at higher dosages”, says CEO, Erik Buntinx, psychiatrist and inventor of PNB02. “Augmentation of the performance of antipsychotic drugs with additional, complementary receptor activities”, Buntinx continues, “provides a unique opportunity to boost the efficacy of schizophrenia treatment with the burden of side-effects remaining limited”.
“Combining the highly selective action on 5HT2A and D4 receptors of low dose pipamperone with the moderate D2 blocking effect of risperidone at limited dose, indeed results in a pharmacological profile that mimicks the pharmacology of clozapine, the universally recognized most effective antipsychotic drug so far”, says Didier de Chaffoy, PhD en Chief Science Officer at PNB. “However, while clozapine is also known for causing severe side-effects, PNB02 is expected to have only a limited side-effect burden due to the profile of its constituents”, de Chaffoy continues.
PNB02 is the second drug development project that is initiated by PNB with a proof-of-Concept phase 2 clinical study running in Belgium. PNB01 is at present in phase 3 clinical development in the United States of America and Canada for the treatment of Major Depression.
Founded in 2006, PNB is a privately held biopharmaceutical company located in Belgium, dedicated to develop best in class CNS therapeutics, based on solid intellectual property. The company’s primary goal is to significantly improve current therapy targeted against mood, anxiety, and psychotic disorders. The two front-running clinical stage proprietary projects (PNB01 and PNB02) are targeted against major depression and schizophrenia, respectively.
About PNB02: PNB02 is the fixed dose combination of low dose risperidone and low dose pipamperone. Risperidone is a well-established ‘atypical’ antipsychotic and pipamperone is a well established mild neuroleptic agent that has been used extensively in some European countries for many years and is a New Drug Entity in the USA. The PNB02 concept has been granted with broad IP coverage.